Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 606
Recruiting: 317
Ph III recruiting: 30
Growth YoY: +37.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (571)

clinicaltrialsPublishedShowing 451–500 of 607 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00669019	Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery	completed	Phase 2	23	National Cancer Institute (NCI)NIH	1	May 21, 2014	clinicaltrials
NCT00281957	Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery	completed	Phase 2	109	National Cancer Institute (NCI)NIH	1	May 20, 2014